We previously reported an association between dyslipidemia and endometrial cancers. Osteoporosis is also reported to relate with some cancers. A common etiologic event has been proposed between dyslipidemia and osteoporosis. However, the pattern of interrelationships among dyslipidemia, osteoporosis and endometrial cancer is not well understood. To improve the quality of life of endometrial cancer survivors, these relationships should be determined. This study included 179 Japanese menopausal women who underwent bilateral salpingo-oophorectomy, including 114 women with incident endometrial cancer and 65 without endometrial cancer. The women were categorized according to dyslipidemia status. Bone mineral density was measured and compared between groups. Osteoporosis was statistically more frequent in women with hypertriglyceridemia who did not have endometrial cancer. In contrast, osteoporosis was statistically less frequent in women with hypertriglyceridemia who had endometrial cancer. In this cross-sectional study in a Japanese population, osteoporosis was associated with hypertriglyceridemia in post-menopausal women without endometrial cancer, but was less frequent in endometrial cancer survivors with hypertriglyceridemia.
Introduction
Since the aging population in developed countries is growing, strategies to improve activities of daily living and quality of life (QOL) are urgently needed. Cardiovascular disease and bone fracture are important causes of disability requiring support and long-term care in the elderly.
Our recent research revealed that hypertriglyceridemia is frequent in endometrial cancer (EC) survivors (1) . Previous studies have reported that dyslipidemia is an independent risk factor for decreased bone mass in post-menopausal women (2, 3) . The standard treatment for EC is total abdominal hysterectomy and bilateral salpingooophorectomy (BSO) due to its estrogen-dependency. Estrogen also affects both serum lipid levels and bone mass. Long-term lack of estrogen causes dyslipidemia as well as osteoporosis (OP) in women. The number of pre-menopausal EC survivors who undergo BSO is likely to increase in the future because the incidence of EC at a younger age is increasing in many countries (4) . BSO places women at high risk for multiple adverse events, including OP and dyslipidemia, along with subsequent bone fracture, atherosclerosis and cerebrovascular and cardiovascular diseases (5) .
As the incidence rates of dyslipidemia, OP and EC are simultaneously increasing, understanding the relationships among serum lipid levels, bone mass and EC is critical. Understanding the relationship between serum lipid levels and bone mass in EC survivors is an unmet need to improve the QOL of EC survivors. Therefore, we compared serum lipid levels and bone mass in EC survivors and women without EC who underwent BSO.
In this study, we assessed the association between bone mass and serum lipid levels, and sub-analyzed the data between EC and non-EC cases. Our report may improve follow-up systems to enhance QOL for post-menopausal women. Additionally, this attempt to determine the biological characteristics of EC may also enable the development of surveillance systems for EC survivors as well as the future identification of preventive or therapeutic targets and biomarkers associated with serum lipids or OP.
Patients and methods
This study is a subanalysis of our previous study, and all cases were included in our previous study (1) .
One hundred seventy-nine of the 946 women who had BSO surgery in the Department of Obstetrics and Gynecology, Keio University Hospital (Tokyo, Japan) from 2007 to 2011 were included in this study (Table 1) . One hundred fourteen women were EC patients (including atypical endometrial hyperplasia patients), and 65 did not have EC (non-EC). Because women can experience dyslipidemia or OP subsequent to ovarian dysfunction caused by pre-menopausal oophorectomy, participants were divided into two groups depending on whether they had undergone BSO before or after menopause ( pre-menopausal and post-menopausal BSO groups, respectively). The pre-menopausal BSO group included 48 non-EC patients and 58 EC patients, and the post-menopausal BSO group included 17 non-EC patients and 56 EC patients. Age, time interval from surgical menopause in the pre-menopausal BSO group, time interval from natural menopause in the post-menopausal BSO group, and body mass index (BMI) were analyzed ( Table 1) .
The same eligibility criteria were applied as in our previous study (1), as follows: patients (i) who had undergone BSO, (ii) ≥20 years of age and (iii) not deemed to be ineligible for participation for any other reason. Exclusion criteria for this study included the presence of non-epithelial tumors, multiple primary cancers accompanying EC, estrogen replacement therapy use, hypothyroidism, hypertension, diabetes mellitus, familial hypercholesterolemia, diagnosed secondary OP, steroid use, prevalent fracture and ongoing treatment for dyslipidemia or OP.
Serum lipid, triglyceride (TG) and low-density lipoprotein cholesterol levels were measured. Blood collected after fasting was used to measure serum lipid levels, thereby avoiding any dietary influences that could cause inconsistent results across patients. The Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases (2012 version) were used to diagnose dyslipidemia (6) .
Bone mineral density (BMD) of the lumbar spine was measured using dual energy X-ray absorptiometry (Prodigy; GE Healthcare Japan, Tokyo, Japan). Young adult mean (%) value was calculated, and OP was diagnosed. Primary OP was diagnosed using the criteria proposed by the Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis (year 2012 revision) (7) .
Statistical analysis was performed as described in our previous study (1) .
We provided a verbal explanation of the study and explanatory documents to recruited patients before they gave written informed consent. This study was conducted with approval from the ethics committee of the School of Medicine, Keio University (approval number: 20070081). Table 1 lists the patient characteristics of the EC cases and non-EC controls according to oophorectomy status. In the overall patient population, the non-EC group was significantly younger than EC group (P = 0.01). However, among patients who underwent premenopausal BSO and patients who underwent post-menopausal BSO, the EC and non-EC groups did not differ with regard to age (P = 0.41, 0.94, respectively). The interval from surgical menopause and the interval from natural menopause were not significantly different between the EC and non-EC groups among patients who underwent pre-menopausal BSO and those who underwent postmenopausal BSO, respectively (P = 0.08 and 0.71, respectively). BMI was significantly higher in the EC group than in the non-EC group in the overall patient population and among patients who underwent pre-menopausal or post-menopausal BSO (P = , respectively). Table 2 shows the relationship between serum lipid levels and OP. OP was significantly more frequent among women with hypertriglyceridemia in the non-EC group [P = 0.04, odds ratio (OR) = 12.25]. In contrast, OP was significantly less frequent among women with hypertriglyceridemia in the EC group (P = 0.01, OR = 0.16).
Results
1
Discussion
Dyslipidemia is a marker of metabolic syndrome (MetS) and is assuming an increasingly important role in the assessment and management of cardiovascular disease risk (8) . The observed incidence of MetS during the post-menopausal period is increasing. MetS, initially defined as a risk factor for cardiovascular disorders, has recently been associated with OP and various cancers (8) (9) (10) (11) (12) .
Some studies have reported an association between dyslipidemia and decreased bone mass in post-menopausal women (2,3). Muhlen et al. (13) examined the association of MetS with BMD, OP and osteoporotic fracture in 417 men and 671 women in the Rancho Bernardo Study. They reported that incident clinical fractures were 2.6 times (95% confidence interval 1.2-5.4, P = 0.01) more likely to occur in participants with MetS compared with participants without MetS. Sex-specific logistic regression models adjusted for age, BMI, estrogen use, exercise, calcium supplements and alcohol intake indicated that MetS significantly increased the odds of incident fractures in women (odds ratio = 3.76, 95% confidence interval, 1.27-11.13, P = 0.02). In an observational study of 1176 elderly women 60-85 years of age, Bagger et al. (14) found a significant association between hypertriglyceridemia and vertebral fractures. Animal studies have also indicated a role for dyslipidemia in the development of OP. In a micro-computed tomography analysis of mice fed a high-fat/high-cholesterol or low-fat/ no-cholesterol diet for 4 months, Pelton et al. (15) concluded that hypercholesterolemia promotes osteoclastogenesis. In contrast, some conflicting reports have concluded that TGs demonstrate a positive association with bone density among women (16, 17) . The Tromsø study, a population-based, 6-year follow-up study of 27 159 people from the municipality of Tromsø, Norway, conducted from 1994 to 2001, concluded that hypertriglyceridemia and BMI were associated with reduced fracture risk (16). Yamaguchi et al. (18) reported a positive and independent association between high-density lipoprotein cholesterol and BMD at the lumbar spine, femoral neck and total body in 214 Japanese post-menopausal women 47-86 years of age.
In that study, plasma TG levels were significantly lower in women with vertebral fractures than in those without fractures.
Some studies have reported an association between EC and the risk of dyslipidemia (1, 12, 19) . These findings suggest that common metabolic abnormalities may act to increase dyslipidemia, OP and EC risk, but detailed data on the pathways connecting these conditions are limited. Hypertension and impaired glucose metabolism are also important factors in the relationship between MetS and OP. Because our present study excluded these factors and the number of subjects with OP was small, further large-scale analysis is required. However, the observed relationship of lipid metabolism with bone metabolism and EC is important for a number of reasons. First, even if a patient is cancer-free and does not die due to EC, the cause of death may be cerebrovascular or cardiovascular disease due to dyslipidemia or bone fracture due to OP. Therefore, the prevention of these diseases may lead to an improved QOL for EC survivors as well as post-menopausal women in general. TG levels are elevated in EC patients (1) . Furthermore, we confirmed that OP occurs more frequently in non-EC hypercholesterolemia patients. Cerebrovascular or cardiovascular events can be prevented in these patients by treating dyslipidemia during follow-up.
Second, the interrelationship between serum lipid and bone metabolism in EC patients is vital to understanding EC carcinogenesis. Metabolomics, the comprehensive study of low-molecular weight metabolites, has recently been used to detect some cancers; however, very few metabolomic or lipidomic analyses have been reported for EC. Nielsen et al. (20) reported that statin use in patients with cancers was associated with reduced cancer-related mortality. Prevention or treatment of dyslipidemia using statins may decrease the incidence rate of EC. Mundy et al. (21) reported an anabolic effect of statins in cultured mouse and human bone cells. Both simvastatin and lovastatin enhanced the expression of bone morphogenetic protein-2 mRNA (21, 22) . Hypertriglyceridemia may be a potential biomarker for EC patients, who could be administered a statin as adjuvant therapy for EC through drug repositioning, that is, application of known or approved drugs to new indications.
Our study highlights the significance of hypertriglyceridemia as a risk factor for OP in post-menopausal women without EC but not in EC survivors. BMI was significantly higher in non-EC than EC cases (Table 1) , which may why dyslipidemia is not a risk factor for OP in EC survivors. Further metabolomic, lipidomic and pathway analyses may resolve the underlying mechanism linking lipid metabolism, bone metabolism and EC, with the aim to develop new therapies including drug repositioning for these diseases.
An important unanswered question remains as to why OP was less frequent in women with hypertriglyceridemia and EC, but it is possible that hormonal factors are involved. Abnormalities in lipid metabolism may be common factors underlying OP, atherosclerosis and endometrial cancer. Future analyses should reveal insights into the carcinogenic process of EC, and new findings using these comprehensive strategies will hopefully lead to targeted drug development or drug repositioning strategies. Further randomized controlled studies using statins, as possible drug-repositioning candidates, are required to confirm our results.
Our report has some limitations due to the lack of statistical power, especially regarding the number of OP patients, which did not permit us to perform multivariate analysis. Aging, BMI or nutritional factors may be cofactors. Furthermore, with resection of both ovaries, the body fat and visceral fat produce estrone (E1), levels of which depend on fat volume. However, we did not evaluate E1 level, which may correlate with BMI. Further large-scale analysis with adjustment for cofounders by multiple regression analysis is needed to confirm our results. In addition, we did not evaluate atherosclerosis status. Some studies have reported that hypercholesterolemia or dyslipidemia promotes osteoclastogenesis in animals. However, we could not find any animal studies that focused on the relationship between hypertriglyceridemia and OP. To better understand the relationship between hypertriglyceridemia and OP, more data from basic research are required.
We examined the association between dyslipidemia and OP or EC. Our report revealed that OP was more frequent in women with hypertriglyceridemia without EC, but that OP was less frequent in women with hypertriglyceridemia with EC. Hypertriglyceridemia.
